

村松 慎一 (Shin-ichi Muramatsu)

〔原著〕

1. Asari, S., Fujimoto, K., Miyauchi, A., Sato, T., Nakano, I. & Muramatsu, S.*. Subregional 6-[18F]fluoro-L-m-tyrosine uptake in the striatum in Parkinson's disease. *BMC Neurol.* 11-35(2011). doi:10.1186/1471-2377-11-35
2. Tokuoka, H., Muramatsu, S., Ichinose, C., Sakane, H., Kojima, M., Aso, Y., Nomura, T., Metzger, D. & Ichinose, H*. Compensatory regulation of dopamine after ablation of the tyrosine hydroxylase gene in the nigrostriatal projection. *J Biol Chem.* **286**, 43549-43558 (2011). doi:10.1074/jbc.M111.284729
3. Miyamoto, M., Miyamoto, T., Iwanami, M., Muramatsu, S., Asari, S., Nakano, I. & Hirata, K*. Preclinical substantia nigra dysfunction in rapid eye movement sleep behaviour disorder. *Sleep Med.* **13**, 102-106(2012). doi:10.1016/j.sleep.2011.03.024.
4. Jin, D., Muramatsu, S., Shimizu, N., Yokoyama, S., Hirai, H., Yamada, K., Liu, HX., Higashida, C., Hashii, M., Higashida, A., Asano, M., Ohkuma, S. & Higashida, H*. Dopamine release via the vacuolar ATPase V0 sector c-subunit, confirmed in N18 neuroblastoma cells, results in behavioral recovery in hemiparkinsonian mice. *Neurochem Int.* [In press] doi:10.1016/j.neuint.2011.12.021

〔著書・総説〕

1. Kondo, Y., Okuno, T., Asari, S. & Muramatsu, S.*.: Cell therapy for Parkinson's disease. Clinical implications of fetal transplantation in Medicine (editors: Stubblefield P and Bhattacharya N), Springer-Verlag. [In press]
2. Muramatsu, S.*, Asari, S.: Assessment of dopaminergic function in Parkinson's disease by SPECT/PET. Horizons in Neuroscience Research Volume 7, Nova Publishers. [In press]
3. Muramatsu, S.*.: Gene therapy for continuous dopamine production in Parkinson's disease. Dopamine: Functions, Regulation and Health Effects, Nova Publishers. [In press]

〔国際学会〕

1. Asari, S., Fujimoto, K., Kato, S., Mizukami, H., Ikeguchi, K., Kawakami, T., Urabe, M., Watanabe, E., Sato, T., Ozawa, K., Nakano, I. & Muramatsu, S.: PET assessment of the aromatic L-amino acid decarboxylase gene expression in a phase I gene therapy study for Parkinson's disease. 15th International Congress of Parkinson's Disease and Movement Disorders, 2011.6.9, Toronto, Canada.

〔国内学会〕

1. Muramatsu, S.: A phase I study of aromatic L-amino acid decarboxylase gene therapy for Parkinson's disease. The 17th Annual Meeting of the Japan Society of Gene Therapy, 2nd Takara Bio Award Lecture, Jul 15, 2011, Fukuoka. (abstract p102)
2. Muramatsu, S., Fujimoto, K., Kato, S., Asari, S., Mizukami, H., Ikeguchi, K., Kawakami, T., Urabe, M., Kume, A., Sato, T., Watanabe, E., Ozawa, K. & Nakano, I.: AADC gene therapy for Parkinson's disease: Four years of follow-up. The 17th Annual Meeting of the Japan Society of Gene Therapy, Best Presentation, Jul 15, 2011, Fukuoka. (abstract p107)
3. Muramatsu, S.: In vivo imaging in cell and gene therapy for Parkinson's disease. The 17th Annual Meeting of the Japan Society of Gene Therapy, Jul 17, 2011, Fukuoka. (abstract p91)
4. Muramatsu, S.: Gene therapy for Parkinson's disease: Four years follow-up. The 8th International Symposium, Sep 21, 2011, Nikko. (abstract p20-21)

5. Muramatsu, S.: Gene therapy: the state of the art. 6th International Expert Meeting on the Treatment of Parkinson's disease, Oct 30, 2011, Tokyo.

〔招待講演・セミナー〕

1. Muramatsu, S.: Gene therapy for Parkinson's disease: Strategies for the local production of dopamine. The Federation of European Biochemical Societies 36th FEBS Congress, 2011.6.30, Torino, Italy.

〔その他〕

新聞発表

『パーキンソン病遺伝子治療 3年以上効果が持続 自治医大』日本経済新聞(2011/9/17 朝刊)